 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CRISPR Therapeutics's Options Frenzy: What You Need to Know

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics...

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics

ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference

Investors are always on the lookout for new stocks to buy. We're looking for bargains, high-potential stocks, and dividend giants.
One area of the market that's getting a lot of attention is gene...

2 stocks to buy in the high potential gene editing space

Crispr Therapeutics AG (CRSP Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 1. Analyst Salim Sy...

Buy Rating Affirmed for Crispr Therapeutics AG on Promising Gene Editing Developments and Expanding Treatment Pipeline

ZUG, Switzerland and BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious...

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics (NASDAQ:CRSP) stock has been falling over the past month. Without any milestone announcements since it gained its second U.S. r...

Are Investors Vastly Underestimating CRISPR Therapeutics Stock (NASDAQ:CRSP)?

The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them.Three Motley Fool contributors believe they've identified three...

3 Unstoppable Stocks to Buy Hand Over Fist in April

Kingswood Wealth Advisors LLC acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the...

Kingswood Wealth Advisors LLC Invests $281,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans...

Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Volume (M)	514,759.00
52-Wk High	$91.10
52-Wk Low	$37.55

CRSP CRISPR Therapeutics AG

About

Feed

News

Sentiment

Earnings

Fundamentals